Joshua Gustine

3.2k total citations
67 papers, 1.6k citations indexed

About

Joshua Gustine is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Joshua Gustine has authored 67 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Genetics, 31 papers in Pathology and Forensic Medicine and 13 papers in Hematology. Recurrent topics in Joshua Gustine's work include Chronic Lymphocytic Leukemia Research (58 papers), Lymphoma Diagnosis and Treatment (30 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Joshua Gustine is often cited by papers focused on Chronic Lymphocytic Leukemia Research (58 papers), Lymphoma Diagnosis and Treatment (30 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Joshua Gustine collaborates with scholars based in United States, Netherlands and Italy. Joshua Gustine's co-authors include Dennis Jones, Steven P. Treon, Jorge J. Castillo, Kirsten Meid, Zachary R. Hunter, Toni Dubeau, Guang Yang, Lian Xu, Christopher J. Patterson and Maria Demos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Joshua Gustine

63 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joshua Gustine United States 18 1.1k 967 486 386 227 67 1.6k
J. Jaubert France 15 879 0.8× 829 0.9× 356 0.7× 431 1.1× 23 0.1× 46 1.7k
Tycho Baumann Spain 15 691 0.6× 610 0.6× 650 1.3× 156 0.4× 39 0.2× 49 1.5k
Dorottya Csuka Hungary 23 977 0.9× 314 0.3× 727 1.5× 492 1.3× 47 0.2× 95 1.6k
Éliane Duchayne France 18 470 0.4× 356 0.4× 204 0.4× 701 1.8× 77 0.3× 38 1.2k
Gilles Lugassy Israel 16 254 0.2× 224 0.2× 191 0.4× 217 0.6× 18 0.1× 55 779
Ricardo Parody Spain 12 445 0.4× 342 0.4× 235 0.5× 945 2.4× 22 0.1× 31 1.5k
A. Gerards Netherlands 14 383 0.3× 268 0.3× 336 0.7× 749 1.9× 33 0.1× 29 2.0k
Barbara Ruggiero Italy 14 239 0.2× 542 0.6× 335 0.7× 141 0.4× 43 0.2× 26 1.6k
Jordi Juncà Spain 13 205 0.2× 177 0.2× 194 0.4× 242 0.6× 15 0.1× 83 742
Takahiko Sugihara Japan 16 139 0.1× 101 0.1× 279 0.6× 166 0.4× 45 0.2× 72 1.0k

Countries citing papers authored by Joshua Gustine

Since Specialization
Citations

This map shows the geographic impact of Joshua Gustine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Gustine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Gustine more than expected).

Fields of papers citing papers by Joshua Gustine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Gustine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Gustine. The network helps show where Joshua Gustine may publish in the future.

Co-authorship network of co-authors of Joshua Gustine

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Gustine. A scholar is included among the top collaborators of Joshua Gustine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Gustine. Joshua Gustine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2025). Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Advances. 9(12). 3026–3030. 1 indexed citations
2.
Castillo, Jorge J., Shayna Sarosiek, Andrew R. Branagan, et al.. (2024). Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia. Blood Advances. 8(9). 2133–2137. 1 indexed citations
3.
Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2024). OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S4–S5. 1 indexed citations
4.
Munshi, Manit, Xia Liu, Amanda Kofides, et al.. (2024). ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells. British Journal of Haematology. 205(5). 1866–1872.
5.
Gustine, Joshua, Andrew Staron, Lisa Mendelson, et al.. (2023). Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Advances. 7(20). 6080–6091. 9 indexed citations
6.
Sarosiek, Shayna, Joshua Gustine, Catherine Flynn, et al.. (2023). Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. British Journal of Haematology. 201(5). 897–904. 13 indexed citations
7.
Gustine, Joshua, Shayna Sarosiek, Catherine Flynn, et al.. (2021). Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 107(5). 1163–1171. 9 indexed citations
8.
Gustine, Joshua & Dennis Jones. (2020). Immunopathology of Hyperinflammation in COVID-19. American Journal Of Pathology. 191(1). 4–17. 330 indexed citations
9.
Castillo, Jorge J., Joshua Gustine, Kirsten Meid, et al.. (2020). Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. HemaSphere. 4(3). e363–e363. 11 indexed citations
10.
Gustine, Joshua, John R. Haserick, Erik C. Hett, et al.. (2019). Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium. Current Microbiology. 76(4). 398–409. 4 indexed citations
11.
Castillo, Jorge J., Kirsten Meid, Joshua Gustine, et al.. (2017). Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia. Blood. 130. 1487–1487. 2 indexed citations
12.
Treon, Steven P., Kirsten Meid, Joshua Gustine, et al.. (2017). Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial. Blood. 130. 2766–2766. 14 indexed citations
13.
Meid, Kirsten, Toni Dubeau, Patricia Severns, et al.. (2017). Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia. Blood. 130. 2772–2772. 13 indexed citations
14.
Castillo, Jorge J., Joshua Gustine, Kirsten Meid, et al.. (2017). Acquired Von Willebrand Disease in Patients with Waldenström Macroglobulinemia. Blood. 130. 1088–1088. 2 indexed citations
15.
Treon, Steven P., Zachary R. Hunter, Joshua Gustine, et al.. (2017). MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia. Blood. 130. 4006–4006. 1 indexed citations
16.
17.
Gustine, Joshua, Kirsten Meid, Toni Dubeau, et al.. (2017). Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia. Blood. 130. 4051–4051. 2 indexed citations
18.
Munshi, Manit, Xia Liu, Lian Xu, et al.. (2017). Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in Waldenstrom's Macroglobulinemia. Blood. 130. 2539–2539. 1 indexed citations
19.
Vos, Josephine M. I., Joshua Gustine, Helmut G. Rennke, et al.. (2016). Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. British Journal of Haematology. 175(4). 623–630. 56 indexed citations
20.
Treon, Steven P., Nicholas Tsakmaklis, Kirsten Meid, et al.. (2016). Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. Blood. 128(22). 2984–2984. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Jaubert Breakdown of academic impact, for papers by Tycho Baumann Breakdown of academic impact, for papers by Dorottya Csuka Breakdown of academic impact, for papers by Éliane Duchayne Breakdown of academic impact, for papers by Gilles Lugassy Breakdown of academic impact, for papers by Ricardo Parody Breakdown of academic impact, for papers by A. Gerards Breakdown of academic impact, for papers by Barbara Ruggiero Breakdown of academic impact, for papers by Jordi Juncà Breakdown of academic impact, for papers by Takahiko Sugihara
Rankless by CCL
2026